Response Genetics, Inc. Announces Appointment Of Stephanie Astrow, Ph.D., As Vice President, Research And Development

Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced today the addition of Stephanie H. Astrow, Ph.D., as the Company’s Vice President for Research and Development. In her role, Dr. Astrow will be responsible for leading the company’s research and development programs, as well as identifying and incorporating new technologies into the services that the Company provides to the medical community.

“With her strong background in the oncology molecular diagnostics industry we believe Stephanie is the perfect fit to lead our R&D efforts,” said Thomas Bologna, Chairman and Chief Executive Officer of Response Genetics. “Stephanie’s track record of identifying and developing biomarker assays and driving scientific innovation to expand business will be a tremendous asset to us and we are looking forward to her contributions.”

Dr. Astrow brings extensive experience in molecular diagnostics research and development as well as operational experience to her role at Response Genetics. Most recently, Dr. Astrow was Scientific Director for Oncology at Quest Diagnostics, the largest global provider of diagnostic testing. At Quest, she played a key role in expanding business by introducing new assays and services, as well as coordinating development strategy for companion diagnostics with key pharmaceutical companies. Prior to her work at Quest, Dr. Astrow served as Vice President and Director of Oncology at Pathway Diagnostics, and Vice President, Scientific Director of Impath, Inc. Dr. Astrow received a Bachelor of Arts in Biology and Medicine at Brown University, and her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She also holds a Masters of Business Administration from Pepperdine University.

Dr. Astrow, commenting on her appointment said, “I couldn’t be more excited to be joining Response Genetics, a company that matches my background and interests very well. I look forward to putting my skills and experience to work in helping people with cancer, and being part of a company that is both patient-centric and well suited to prosper in the exciting field of personalized diagnostics.”

If you liked this article you might like

3 Stocks Under $10 Triggering Breakout Trades

3 Stocks Moving The Health Services Industry Upward

3 Stocks Pushing The Health Services Industry Lower

3 Health Services Stocks Nudging The Industry Higher

3 Stocks Pushing The Health Services Industry Lower